HSBC TO. BULL GIS/ DE000TD9GKV6 /
| 6/13/2024 9:35:16 PM | Chg.-0.0100 | Bid9:59:03 PM | Ask9:59:03 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 1.2600EUR | -0.79% | 1.2300 Bid Size: 50,000 |
1.2600 Ask Size: 50,000 |
Gilead Sciences Inc | 50.3832 USD | 12/31/2078 | Call |
GlobeNewswire
6/10
Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus He...
GlobeNewswire
5/22
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congres...
GlobeNewswire
5/14
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
GlobeNewswire
5/9
MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim ...
GlobeNewswire
5/9
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
5/8
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
GlobeNewswire
5/8
Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
GlobeNewswire
4/29
Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Eva...
GlobeNewswire
4/19
ACTG Announces Launch of Clinical Trial Evaluating Combination of Three Novel Immune-based Therapies...
GlobeNewswire
4/10
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Upda...
GlobeNewswire
4/2
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
GlobeNewswire
4/1
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Fin...
GlobeNewswire
3/28
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlight...
GlobeNewswire
3/28
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
GlobeNewswire
3/22
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highl...
GlobeNewswire
3/18
CIO Celebrates Innovations in Business Technology with 2024 CIO 100 & Hall of Fame Awards
GlobeNewswire
3/11
Hyku Biosciences, a Covalent Precision Medicine Company, Announces CEO Transition for its Next Phase...
GlobeNewswire
2/29
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay The...
GlobeNewswire
2/29
Abingworth Announces a Strategic Development Financing Agreement with Gilead Sciences; Establishes J...
GlobeNewswire
2/28
CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corpo...
